Granite Point Capital Management, L.P. Aurinia Pharmaceuticals Inc. Transaction History

Granite Point Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	SELL	$10.93 - $23.55 $1.09 Million - $2.36 Million	-100,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$10.0 - $14.52 $1 Million - $1.45 Million	100,000 New	100,000 $1.3 Million
Q1 2020 May 12, 2020	SELL	$11.34 - $21.46 $1.13 Million - $2.15 Million	-100,000 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$3.88 - $21.42 $388,000 - $2.14 Million	100,000 New	100,000 $2.03 Million

191

56.7M

499K

637K

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.01B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.